Targeted disruption of leukotriene B4 receptors BLT1 and BLT2: A critical role for BLT1 in collagen-induced arthritis in mice

Journal of Immunology

Volumn 176, Issue 10, 2006, Pages 6254-6261

  Shao, Wen Hai ^a,b   Del Prete, Annalisa ^a,c   Bock, Cheryl B ^d   Haribabu, Bodduluri ^a,b,e  

^a UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^b University of Louisville School of Medicine   (United States)

^c UNIVERSITY OF BARI   (Italy)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; COLLAGEN ANTIBODY; G PROTEIN COUPLED RECEPTOR; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR; PROTEIN BLT1; PROTEIN BLT2; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTHRITIS; ARTICLE; BONE EROSION; CELL INFILTRATION; CONTROLLED STUDY; DISEASE SEVERITY; FIBROSIS; GENE DISRUPTION; HISTOPATHOLOGY; INFLAMMATION; INFLAMMATORY CELL; MOUSE; NONHUMAN; PERITONEUM EXUDATE; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY;

EID: 33646484781     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.10.6254     Document Type: Article

References (50)

1. Goldblatt, F., and D. A. Isenberg. 2005. New therapies for rheumatoid arthritis. Clin. Exp. Immunol. 140: 195-204.
2. Courtenay, J. S., M. J. Dallman, A. D. Dayan, A. Martin, and B. Mosedale. 1980. Immunisation against heterologous type II collagen induces arthritis in mice. Nature 283: 666-668.
3. Wooley, P. H., H. S. Luthra, J. M. Stuart, and C. S. David. 1981. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J. Exp. Med. 154: 688-700.
4. Anthony, D. D1, and T. M. Haqqi. 1999. Collagen-induced arthritis in mice: an animal model to study the pathogenesis of rheumatoid arthritis. Clin. Exp. Rheumatol. 17: 240-244.
5. Holmdahl, R., R. Bockermann, J. Backlund, and H. Yamada. 2002. The molecular pathogenesis of collagen-induced arthritis in mice-a model for rheumatoid arthritis. Ageing Res. Rev. 1: 135-147.
6. b) mice: new insights into an important disease model of rheumatoid arthritis. Eur. J. Immunol. 30: 1568-1575.
7. Campbell, I. K., K. O'Donnell, K. E. Lawlor, and I. P. Wicks. 2001. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J. Clin. Invest. 107: 1519-1527.
8. Keffer, J., L. Probert, H. Cazlaris, S. Georgopoulos, E. Kaslaris, D. Kioussis, and G. Kollias. 1991. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10: 4025-4031.
9. Williams, R. O., M. Feldmann, and R. N. Maini. 1992. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 89: 9784-9788.
10. 4: metabolism and signal transduction. Arch. Biochem. Biophys. 385: 231-241.
11. 4 receptors in the development of atherosclerosis: potential mechanisms. Anerioscler. Thromb. Vase. Biol. 24: 369-375.
12. 4 strongly increases monocyte chemoattractant protein-1 in human monocytes. Anerioscler. Thromb. Vasc. Biol. 24: 1783-1788.
13. Luster, A. D., and A. M. Tager. 2004. T-cell trafficking in asthma: lipid mediators grease the way. Nat. Rev. Immunol. 4: 711-724.
14. Jala, V. R., and B. Haribabu. 2004. Leukotrienes and atherosclerosis: new roles for old mediators. Trends Immunol. 25: 315-322.
15. 4, a mediator of inflammation present in synovial fluid in rheumatoid arthritis. Ann. Rheum. Dis. 42: 677-679.
16. 4 and immunological parameters in rheumatoid synovial fluids. Inflammation 15: 497-503.
17. Hawkes, J. S., L. G. Cleland, S. M. Proudman, and M. J. James. 1994. The effect of methotrexate on ex vivo lipoxygenase metabolism in neutrophils from patients with rheumatoid arthritis. J. Rheumatol. 21: 55-58.
18. 4 plays a critical role in the progression of collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 92: 517-521.
19. Kuwabara, K., K. Yasui, H. Jyoyama, T. Maruyama, J. H. Fleisch, and Y. Hori. 2000. Effects of the second-generation leukotriene B-4 receptor antagonist, LY293111Na, on leukocyte infiltration and collagen-induced arthritis in mice. Eur. J. Pharmacol. 402: 275-285.
20. Griffiths, R. J., M. A. Smith, M. L. Roach, J. L. Stock, E. J. Stam, A. J. Milici, D. N. Scampoli. J. D. Eskra, R. S. Byrum, B. H. Koller, and J. D. McNeish. 1997. Collagen-induced arthritis is reduced in 5-lipoxygenase- activating protein-deficient mice. J. Exp. Med. 185: 1123-1129.
21. Yokomizo, T., T. Izumi, K. Chang, Y. Takuwu, and T. Shimizu. 1997. A G-protein-coupled receptor for leukotriene B-4 that mediates chemotaxis. Nature 387: 620-624.
22. Yokomizo, T., K. Kato, K. Terawaki, T. Izumi, and T. Shimizu. 2000. A second leukotriene B-4 receptor. BLT2: A new therapeutic target in inflammation and immunologieal disorders. J. Exp. Med. 192: 421-431.
23. Hashimoto, A., H. Endo, I. Hayashi, Y. Murakami, H. Kitasato, S. Kono, T. Matsui, S. Tanaka, A. Nishimura, K. Urabe, et al. 2003. Differential expression of leukotriene B4 receptor subtypes (BLT1 and BLT2) in human synovial tissues and synovial fluid leukocytes of patients with rheumatoid arthritis. J. Rheumatol. 30: 1712-1718.
24. 4 receptor BLT1 mediates early effector T cell recruitment. Nat. Immunol. 4: 982-990.
25. 4 receptor 1 in allergen-induced airway hyperresponsiveness. Am. J. Respir. Crit. Care Med. 172: 161-167.
26. Kato, K., T. Yokomizo, T. Izumi, and T. Shimizu. 2000. Cell-specific transcriptional regulation of human leukotriene B-4 receptor gene. J. Exp. Med. 192: 413-420.
27. Haribabu, B., M. W. Verghese, D. A. Steeber, D. D. Sellars, C. B. Bock, and R. Snyderman. 2000. Targeted disruption of the leukotriene B-4 receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. J. Exp. Med. 192: 433-438.
28. Steeber, D. A., P. Engel, A. S. Miller, M. P. Sheetz, and T. F. Tedder. 1997. Ligation of L-selectin through conserved regions within the lectin domain activates signal transduction pathways and integrin function in human, mouse, and rat leukocytes. J. Immunol. 159: 952-963.
29. Haribabu, B., D. V. Zhelev, B. C. Pridgen, R. M. Richardson, H. Ali, and R. Snyderman. 1999. Chemoattractant receptors activate distinct pathways for chemotaxis and secretion: role of G-protein usage. J. Biol. Client. 274: 37087-37092.
30. Youn, J., S. H. Hwang, Z. Y. Ryoo, M. A. Lynes, D. J. Paik, H. S. Chung, and H. Y. Kim. 2002. Metallothionein suppresses collagen-induced arthritis via induction of TGF-beta; and down-regulation of proinflammatory mediators. Clin. Exp. Immunol. 129: 232-239.
31. Kamohara, M., J. Takasaki, M. Matsumoto, T. Saito, T. Ohishi, H. Ishii, and K. Furuiehi. 2000. Molecular cloning and characterization of another leukotriene B-4 receptor. J. Biol. Chan. 275: 27000-27004.
32. 4 receptors. Prostaglandins Leukot. Essent. Fatty Acids 69: 123-134.
33. Pan, M., I. Kang, J. Craft, and Z. Yin. 2004. Resistance to development of collagen-induced arthritis in C57BL/6 mice is due to a defect in secondary, but not in primary, immune response. J. Clin. Immnnol. 24: 481-491.
34. Bullard, D. C., J. M. Mobley, J. M. Justen, L. M. Sly, J. G. Chosay, C. J. Dunn, J. R. Lindsey, A. L. Beaudet, and N. D. Staite. 1999. Acceleration and increased severity of collagen-induced arthritis in P-selectin mutant mice. J. Immunol. 163: 2844-2849.
35. Svensson, L., J. Jirholt, R. Holmdahl, and L. Jansson. 1998. B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin. Exp. Immunol. 111: 521-526.
36. Verdrengh, M., I. M. Jonsson, O. Zaether, E. Bajtner, R. Holmdahl, and A. Tarkowski. 2002. Total abrogation of collagen II-induced arthritis and the B cell response to type II collagen using suboptimal doses of a topoisomerase II antagonist. Ann. Rheum. Dis. 61: 829-831.
37. Dunussi-Joannopoulos, K., G. E. Hancock, A. Kunz, M. Hegen, X. X. Zhou, B. J. Sheppard, J. Lamothe, E. Li, H. L. Ma, P. R. Hamann, et al. 2005. B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model. Blood 106: 2235-2243.
38. Ehinger, M., M. Vestberg, A. C. Johansson, M. Johannesson, A. Svensson, and R. Holmdahl. 2001. Influence of CD4 or CD8 deficiency on collagen-induced arthritis. Immunology 103: 291-300.
39. 4. Nat. Immunol. 4: 974-981.
40. Kitsis, E., and G. Weissmann. 1991. The role of the neutrophil in rheumatoid arthritis. Clin. Orthop. Relat. Res. 265: 63-72.
41. Klickstein, L. B., C. Shapleigh, and E. J. Goetzl. 1980. Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritis. J. Clin. Invest. 66: 1166-1170.
42. Bomalaski, J. S., and M. A. Clark. 1993. Phospholipase A2 and arthritis. Arthritis Rheum. 36: 190-198.
43. Myers, L. K., A. H. Kang, A. E. Postlethwaite, E. F. Rosloniec, S. G. Morham, B. V. Shlopov, S. Goorha, and L. R. Ballou. 2000. The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. Arthritis Rheum. 43: 2687-2693.
44. Ochi, T., Y. Ohkubo, and S. Mutoh. 2003. Role of cyclooxygenase-2, but not cyclooxygenase-1. on type 11 collagen-induced arthritis in DBA/IJ mice. Biochem. Pharmacol. 66: 1055-1060.
45. Hegen, M., L. Sun, N. Uozuini, K. Kume, M. E. Goad, C. L. Nickerson-Nutter, T. Shimizu, and J. D. Clark. 2003. Cytosolic phospholipase A2α-deficient mice are resistant to collagen-induced arthritis. J. Exp. Med. 197: 1297-1302.
46. Matheson, A. J., and D. P. Figgitt. 2001. Rofecoxib: a review of its use in the management of osteoarlhritis. acute pain and rheumatoid arthritis. Drugs 61: 833-865.
47. Hedner, T., and A. Himmelmann. 2004. Cardiovascular complications of COX2 selective inhibitors cause considerable concern. Blood Press 13: 260-261.
48. 4. J. Immunol. 171: 1009-1015.
49. 4-induced CDI 1B/CD18 (Mac-1) expression by BIIL 284, a new long acting LTB4 receptor antagonist, in patients with rheumatoid arthritis. Ann. Rheum. Dis. 63: 170-176.
50. Weinhlatt, M. E., J. M. Kremer, J. S. Coblyn, S. Helfgott, A. L. Maier, G. Petrillo, B. Henson, P. Rubin, and R. Sperling. 1992. Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis. J. Rheumatol. 19: 1537-1541.